INNOCAN PHARMA Corp
INNPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $29,437 | $13,657 | $2,559 | $196 |
| % Growth | 115.5% | 433.7% | 1,205.6% | – |
| Cost of Goods Sold | $3,250 | $1,679 | $452 | $75 |
| Gross Profit | $26,187 | $11,978 | $2,107 | $121 |
| % Margin | 89% | 87.7% | 82.3% | 61.7% |
| R&D Expenses | $1,549 | $1,796 | $1,526 | $1,399 |
| G&A Expenses | $4,753 | $3,078 | $3,983 | $3,707 |
| SG&A Expenses | $25,885 | $13,985 | $6,847 | $6,202 |
| Sales & Mktg Exp. | $21,132 | $10,907 | $2,864 | $2,495 |
| Other Operating Expenses | $0 | -$7,606 | $0 | $0 |
| Operating Expenses | $27,434 | $8,175 | $8,373 | $7,601 |
| Operating Income | -$1,247 | $3,803 | -$6,266 | -$7,480 |
| % Margin | -4.2% | 27.8% | -244.9% | -3,816.3% |
| Other Income/Exp. Net | $2,166 | -$7,837 | $2,378 | -$2,611 |
| Pre-Tax Income | $919 | -$4,034 | -$3,888 | -$10,091 |
| Tax Expense | $1,181 | $214 | $1 | $0 |
| Net Income | -$1,834 | -$4,700 | -$3,764 | -$10,047 |
| % Margin | -6.2% | -34.4% | -147.1% | -5,126% |
| EPS | -0.42 | -1.19 | -0.982 | -2.906 |
| % Growth | 64.7% | -21.2% | 66.2% | – |
| EPS Diluted | -0.42 | -1.19 | -0.982 | -2.906 |
| Weighted Avg Shares Out | 4,201 | 3,855 | 3,734 | 3,368 |
| Weighted Avg Shares Out Dil | 4,201 | 3,855 | 3,734 | 3,368 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $23 | $21 | $0 |
| Interest Expense | $7 | $0 | $2 | $13 |
| Depreciation & Amortization | $35 | $34 | $34 | $43 |
| EBITDA | -$1,212 | -$3,770 | -$3,698 | -$7,372 |
| % Margin | -4.1% | -27.6% | -144.5% | -3,761% |